Clinical manifestations and evolution of infection by influenza A (H1N1) in kidney transplant recipients by Freitas, Tainá Veras de Sandes et al.
Original article | artigO Original
136 J Bras Nefrol 2011;33(2):136-141
Authors
Tainá Veras de Sandes Freitas1
Gislaine Ono2
Luci Corrêa2
Pollyane Sousa Gomes2
Nelson Zocoler Galante1
Hélio Tedesco-Silva1
Luís Fernando Aranha 
Camargo2
José Osmar Medina de Abreu 
Pestana1
1Department of Medicine, Discipline 
of Nephrology, Universidade Fede-
ral de São Paulo (UNIFESP).
2Department of Medicine, Discipline 
of Infectology, UNIFESP. 
Submitted on: 11/08/2010 
Accepted on: 21/09/2010
Correspondence to: 
José Osmar Medina de Abreu 
Pestana 
Rua Borges Lagoa, 960  
São Paulo – SP – Brazil 
Zip code: 04038-002 
E-mail: medina@hrim.com.br
Study carried out at Hospital do 
Rim e Hipertensão, UNIFESP.
The authors declare no conflict of 
interest.
Resumo
Introdução: A emergência do surto pandêmi-
co de influenza A, subtipo H1N1, em abril 
de 2009, representou um grande desafio 
para a logística de saúde pública. Embora 
a maioria dos pacientes infectados apresen-
te manifestações clínicas e evolutivas muito 
semelhantes às observadas na influenza sazo-
nal, um número significativo de indivíduos 
evolui com pneumonia e insuficiência respi-
ratória aguda severa. O impacto da infecção 
pelo vírus influenza A, subtipo H1N1, em 
pacientes imunossuprimidos não é determi-
nado. Método: Neste estudo, foram analisa-
das a apresentação clínica e a evolução da in-
fluenza A, subtipo H1N1, em 19 receptores 
de transplante renal. Os pacientes receberam 
confirmação diagnóstica pela técnica de RT-
PCR. O manejo clínico incluiu terapêutica 
antiviral com fosfato de oseltamivir e anti-
bióticos. Resultados: A população estudada 
foi predominantemente de indivíduos do 
sexo masculino (79%), brancos (63%), com 
idade média de 38,6 ± 17 anos e portadores 
de pelo menos uma comorbidade (53%). A 
infecção por influenza A, subtipo H1N1, foi 
diagnosticada em média 41,6 ± 49,6 meses 
após o transplante. Os sintomas mais co-
muns foram: tosse (100%), febre (84%), 
dispneia (79%) e mialgia (42%). Disfunção 
aguda do enxerto foi observada em 42% 
dos pacientes. Cinco pacientes (26%) foram 
admitidos em Unidade de Terapia Intensiva, 
dois (10%) necessitaram de suporte com ven-
tilação invasiva e dois (10%) receberam dro-
gas vasoativas. A mortalidade foi de 10%. 
Conclusões: A disfunção aguda do enxerto 
renal foi um achado frequente, e as carac-
terísticas clínicas, laboratoriais e evolutivas 
foram comparáveis às da população geral. 
Palavras-chave: infecções respiratórias, vírus 
da influenza A subtipo H1N1, fatores de ris-
co, transplante de rim, imunosupressão.
AbstRAct
Introduction: The emergence of the pan-
demic outbreak of influenza A (H1N1) in 
April, 2009, represented a logistic chal-
lenge for public health. Although most in-
fected patients presented clinical and evo-
lutionary manifestations which were very 
similar to seasonal influenza, a significant 
number of individuals developed  pneu-
monia and severe acute respiratory failu-
re. The impact of influenza A (H1N1) in 
immunocompromised patients is not well 
established yet. Method: This study aimed 
to analyze the clinical presentations and 
evolution of influenza A (H1N1) in 19 
kidney transplant recipients. Influenza A 
(H1N1) infection was confirmed by RT-
PCR in all patients. Treatment included 
antiviral therapy with oseltamivir phos-
phate and antibiotics. Results: The stu-
died population was compounded mostly 
of white people (63%), males (79%), at a 
mean age of 38.6 ± 17 years and patients 
with at least one comorbidity (53%). 
Influenza A (H1N1) infection was iden-
tified 41.6 ± 49.6 months after transplan-
tation. Common symptoms included cou-
gh (100%), fever (84%), dyspnea (79%), 
and myalgia (42%). Acute allograft dys-
function was observed in 42% of the pa-
tients. Five patients (26%) were admitted 
to the Intensive Care Unit, two (10%) 
required invasive ventilation support, 
and two (10%) required vasoactive dru-
gs. Mortality rate was 10%. Conclusions: 
Acute renal allograft dysfunction was a 
common finding. Clinical, laboratory, and 
evolutionary characteristics were compa-
rable to those in the general population.
Keywords: respiratory tract infec-
tions, influenza A virus, H1N1 subtype, 
risk factors, kidney transplantation, 
immunosuppression.
Clinical manifestations and evolution of infection by 
influenza A (H1N1) in kidney transplant recipients
Manifestações clínicas e evolução da infecção pelo vírus da 
influenza A (H1N1) em receptores de transplante renal
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IntRoductIon
In April 2009, the World Health Organization (WHO) 
reported the infection caused by a new influenza A vi-
rus subtype (H1N1) in the Mexican population. This 
new subtype was the result of a genetic combination 
of influenza A virus strains, which are capable of in-
fecting human, swine and bird organisms.1 
The number of cases of influenza A H1N1 infec-
tion increased rapidly in Mexico and other countries, 
reaching pandemic proportions.2
Clinical presentation and the evolution of influ-
enza A H1N1 infection are very similar to those of 
seasonal influenza. Less common signs and symptoms 
of seasonal influenza, such as vomit and diarrhea, are 
observed in a significantly larger number of patients.3 
Unfavorable clinical evolution, with pneumonia and 
severe respiratory failure, has been frequent and, as 
opposed to seasonal influenza, has affected mainly 
young patients and pregnant women.4
The impact of influenza A H1N1 infection in 
immunosuppressed patients is not well established. 
Knowing about the clinical impact of this virus in 
this population is essential to establish new policies to 
prevent and treat this important condition.
In this study, the clinical presentations and evo-
lution of influenza A H1N1 were described, with a 
confirmed diagnosis by reverse transcriptase – poly-
merase chain reaction (RT-PCR), in 19 kidney trans-
plant recipients followed up at Hospital do Rim e 
Hipertensão.
methods
Study deSign and data cOllectiOn
This study included 19 kidney transplant recipients, 
admitted at Hospital do Rim e Hipertensão from July 
1st, 2009, to September 31st, 2009 for at least 24 hours, 
and with confirmed influenza A H1N1infection. 
The analyzed data were gathered from medi-
cal files and investigation reports from Sistema de 
Informação de Agravos de Notificação da Secretaria 
Estadual de Saúde, state of São Paulo. The retrospec-
tive study considered demographic data, pneumococ-
cal and influenza A vaccination history, associated 
comorbidities, clinical signs and symptoms, labora-
tory and radiological profile, and the aspects related 
to clinical evolution.
clinical diagnOSiS
Diagnostic routine for influenza A H1N1 infection was 
performed in compliance with the Ministry of Health 
of São Paulo recommendations. Transplant patients 
with suspicion of infection by influenza5 were consi-
dered to be eligible for hospital admission and empiri-
cal treatment with oseltamivir phosphate (Tamiflu®). 
From August 5, 2009 on, with the characterization 
of the pandemic outbreak of influenza A H1N1, mi-
nistry and state recommendations were revised, thus 
being considered for hospital admission only those 
patients with suspicion of acute respiratory infection 
by influenza and patients presenting with severe acute 
respiratory disease or alert signs and symptoms.6 
Severe acute respiratory disease was characterized 
by fever higher than 100ºF, cough and dyspnea with 
or without laryngalgia or gastrointestinal symptoms. 
Alert signs and symptoms were mental confusion, tac-
hypnea, systemic arterial hypotension (systolic blood 
pressure <90 mmHg and diastolic blood pressure <60 
mmHg), and age superior to 65 years. Alert signs and 
symptoms for pediatric patients included flaring of 
the nostrils, intercostal retraction on inspiration, cy-
anosis, dehydration, lack of appetite, vomit, malaise, 
toxemia, and absence of family support.5,6
labOratOry diagnOSiS
Diagnostic screening by rapid QuickVue Influenza 
A+B test (Quidel, San Diego, CA, USA) was performed 
only at the beginning of the pandemic. After August 
7, 2009, considering the transmission of influenza A 
H1N1 within the national territory and the low sen-
sibility of the test, diagnostic screening was no longer 
recommended by the Hospital do Rim e Hipertensão 
Infection Control Commission. 
The infection by influenza A H1N1 was confirmed 
by direct identification of the specific antigen for in-
fluenza by the RT-PCR technique, according to the 
protocol by the Center of Disease Control in USA and 
by WHO,7 in a sample of respiratory secretion ob-
tained from the nasopharynx or trachea. Molecular 
tests were performed at Instituto Adolfo Lutz, São 
Paulo. 
Acute allograft dysfunction was defined as an in-
crease of at least 20% in serum creatinine in com-
parison to basal value. Acute allograft dysfunction 
was classified as mild when serum creatinine eleva-
tions were between 20 and 50% of the basal value; as 
moderate, for values higher than 50%; and as severe 
when dialytic therapy was necessary. 
treatment 
Patients received symptomatic and clinical support 
according to their need. Antiviral treatment with 
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oseltamivir phosphate was carried out in up to 24 
hours after hospital admission, regardless of the ti-
me of symptoms onset. Treatment was predicted to 
last for five days. Complementary therapy with anti-
biotics was used according to clinical and laboratory 
judgment.
StatiStical analySiS
The variables were presented by means of statistical 
and descriptive parameters. Numerical variables we-
re expressed as means and standard deviations, and 
categorical variables, as percentage frequencies. The 
program SPSS version 7.5.1 (SPSS Inc., Chicago, IL. 
USA, 1996) was used for statistical analysis.
Results
During the studied period, 44 patients were admit-
ted to the hospital with flu symptoms and severe 
acute respiratory disease criteria. Rapid test for in-
fluenza A or B was performed in ten patients and 
was positive for influenza A in six of them (60%). 
Influenza A H1N1 infection was confirmed by mole-
cular test in 14 patients. Five other patients who had 
been previously admitted for other indications (one 
due to acute allograft rejection and four due to in-
fectious complications not related to the respiratory 
apparatus) had respiratory symptoms compatible 
with influenza, and then received diagnostic confir-
mation for influenza A H1N1 after the performance 
of molecular test. The 44 patients admitted with se-
vere acute respiratory disease and the 19 diagnosed 
with influenza A H1N1 infection represented, res-
pectively, 1.1 and 0.5% of the population of 4,091 
recipients followed up in the institution during the 
same period. The 19 patients who had a confirmed 
diagnosis for influenza A H1N1 were predominan-
tly adults (38.6 ± 17 years – 8-63), males (79%), 
white (63%), and presented at least one comorbidity 
(53%), as described in Table 1. Influenza A H1N1 
infection was diagnosed 41.6 ± 49.6 (0-170) months 
after transplant. However, five patients (26%) had 
had a transplant less than three months earlier. Most 
patients (37%) received tacrolimus, prednisone and 
mycophelonate (sodium or mofetil) when being diag-
nosed for influenza A H1N1. 
The most common symptoms were: cough 
(100%), fever (84%), dyspnea (79%) and myalgia 
(42%) (Table 2). Mean time between the onset of 
symptoms and hospital admission was 3.3 ± 2.4 
(1-10) days. At hospital admission, eight patients 
(42%) presented with renal allograft dysfunction, 
and three (16%) had acute allograft dysfunction 
during admission. Five patients (26%) reported hav-
ing previous contact with suspicious or confirmed 
cases of influenza A H1N1. Only one patient (5%) 
reported having received the seasonal flu vaccine, 
and two (10%) reported pneumococcal vaccine. The 
main radiologic finding was interstitial infiltrate 
(79%). Only one patient (5%) had a normal chest 
x-ray evaluation (Table 2).
Only one patient was not treated with oseltamivir 
phosphate because the viral infection diagnosis was 
Characteristic n = 19
Age (years) 38.6 ± 17
Male 15 (78.9%)
Body Mass Index (kg/m2) 22 ± 3.6
Ethnicity
White 12 (63.0%)
Black 3 (16.0%)
Brown 4 (21.0%)
Previous comorbidities 10 (52.6%)
Diabetes mellitus 4 (21%)
Cardiopathy 1 (5.3%)
Pneumopathy 1 (5.3%)
Diabetes mellitus + cardiopathy 1 (5.3%)
Diabetes mellitus + cardiopathy + 
pneumopathy
1 (5.3%)
Others 2 (10.5%)
Previous seasonal flu vaccine 1 (5.3%)
Previous pneumococcal infection vaccine 2 (10.5%)
Time after the transplant (months) 41.6 ± 49.6
Type of donor
Live 8 (42.1%)
Deceased 11 (57.9%)
immunosuppression*
CI-MF-PRED 7 (36.80%)
CI -AZA-PRED 5 (26.3%)
MF-PRED 3 (15.8%)
CI -SRL-PRED 1 (5.3%)
CI-MF 1 (5.3%)
SRL-MF-PRED 1 (5.3%)
SRL-PRED 1 (5.3%)
Table 1 general characteriSticS Of kidney 
tranSplant recipientS with influenza 
a Subtype h1n1
*CI: calcineurin inhibitor; PRED: prednisone; AZA: azathioprine; 
MF: mycophelonate (sodium or mofetil); SRL: sirolimo.
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Five patients (26%) were admitted to the Intensive 
Care Unit, two (10%) needed invasive ventilation 
support and two (10%) received vasoactive drugs. 
Two patients (10%) presented unfavorable evolu-
tion of the respiratory tract and died on the first and 
seventh days of follow-up. Mean hospital admittance 
time was 13 ± 12.4 days (Table 3). 
dIscussIon
Clinical and epidemiological monitoring of influenza 
A H1N1 infection in our cohort of kidney transplant 
recipients showed demographic characteristics similar 
to the demographic profile of the general population 
in need of hospital admission and referred by other 
institutions.8-10
According to Oliveira et al., a high percentage of 
patients with severe forms of the disease in the gener-
al population are young adults with other associated 
comorbidities such as chronic respiratory diseases, 
metabolic and endocrine disorders, and pregnancy, as 
well as those who are immunosuppressed by diseases 
or medicines.11 Patients in this study also presented 
with comorbidities, mainly chronic pulmonary dis-
ease, heart failure and diabetes mellitus. None of the 
patients was obese, although many transplant recipi-
ents present with significant weight gain in the post-
operative period,12 and even though this was a risk 
group in the general population.11
Mean transplant time during hospital admission 
was 41.6 months, and 26% of the patients had been 
followed-up for less than three months. Even though 
completed post-mortem, with RT-PCR performed 
with the respiratory tract secretion collected by the 
service of verification of death. This secretion collec-
tion to search for influenza A H1N1 was common 
at the time. Antimicrobial agents were used in 16 
patients (84%) due to a suspicion of bacterial infec-
tion associated with viral infection. Third or fourth 
generation cephalosporins associated with macrolide 
antibiotics were the most used medicines (42% of the 
cases) (Table 3).
Table 3 clinical evOlutiOn and treatment Of 
kidney tranSplant recipientS infected 
by influenza a h1n1
Variables n = 19
Admission to Intensive Care Unit 5 (26.3%)
Need for mechanical ventilation 2 (10.5%)
Need for vasoactive drugs 2 (10.5%)
Antimicrobial treatment 16 (84.2%)
Cephalosporin + macrolide 8 (42.1%)
Cephalosporin + macrolide + 
glycopeptide
3 (15.8%)
Cephalosporin + glycopeptide 3 (15.8%)
Antipseudomonal penicillin + macrolide 
+ glycopeptide
1 (5.3%)
Quinolone 1 (5.3%)
Hospital stay (days) 13 ± 12.4
Death 2 (10.5%)
Table 2 clinical preSentatiOn and 
cOmplementary evaluatiOn Of kidney 
tranSplant recipientS with influenza 
a Subtype h1n1 
Variables n = 19
Time between symptoms onset and 
admission (days) 
3.3 ± 2.4
Signs and symptoms
Cough 19 (100%)
Fever 16 (84.2%)
Dyspnea 15 (78.9%)
Myalgia 8 (42.1%)
Runny nose 7 (36.8%)
Migraine 5 (26.3%)
Chest pain 4 (21.1%)
Throat pain 4 (21.1%)
Diarrhea 3 (15.8%)
Arthralgia 2 (10.5%)
Hypoxemia 2 (10.5%)
Hypotension 2 (10.5%)
Nosocomial infection 5 (26.3%)
Previous contact with a suspicious or 
confirmed case
5 (26.3%)
Rapid test for influenza A or B
Positive for influenza A 6 (31.6%)
Negative 4 (21.1%)
Not performed 9 (47.4%)
Findings in the chest x-ray
No alterations 1 (5.3%)
Interstitial infiltrate 15 (78.9%)
Lobar infiltrate 1 (5.3%)
Mixed infiltrate 2 (10.5%)
Acute allograft dysfunction
Mild 7 (53.8%)
Moderate 2 (15.4%)
Severe 2 (15.4%)
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52% of our patients received the combination of cal-
cineurin, prednisone and azathioprine inhibitors13 as 
initial immunosuppression agents, most studied pa-
tients (37%) received calcineurin, prednisone and my-
cophelonate inhibitors as immunosuppression. 
Despite the fact that these data suggest high im-
munosuppression makes patients susceptible to the 
disease and its more severe forms, the information 
obtained in this study is not sufficient to make a con-
clusion about such association.
The most peculiar clinical presentation of H1N1 
infection in the population of kidney transplant re-
cipients studied here was the high incidence of renal 
dysfunction (58%), when compared to immuno-
competent patients.9,14,15 In spite of the description 
of the association between respiratory tract viral in-
fections and the acute renal allograft rejection,16,17 
none of these events were attributed to acute re-
jection. In these patients, allograft dysfunction was 
attributed to volemic depletion, acute tubular ne-
crosis secondary to sepsis, rhabdomyolysis, or cal-
cineurin inhibitor nephrotoxicity, increased by the 
high blood levels resulting from the pharmacologi-
cal interaction of these drugs with the antimicrobi-
als agents used,15 although many recipients present 
renal allograft dysfunction with no apparent etiol-
ogy during systemic infections.18,19 It is important 
to emphasize that 73% of the allograft dysfunction 
episodes were diagnosed at hospital admission, and 
45% of the patients who presented acute allograft 
dysfunction did not receive simultaneous calcineu-
rin inhibitor and macrolide antibiotics. At the end 
of the observation period, only one patient did not 
fully recover renal function.
Treatment with oseltamivir phosphate was ad-
ministered even 48 hours after symptoms onset (mini-
mum of one day and maximum of ten days after the 
first manifestation). Although there is no evidence of 
benefit for using the antiviral to treat the infection 
in healthy subjects 48 hours after the beginning of 
symptoms,5,20 immunosuppressed patients present de-
lay in the peak of viral replication activity, as well 
as increase in the length of time necessary to com-
pletely depurate the viral load, which indicates that 
the therapeutic benefit for this population might be 
superior.21,22 The difficulty to define the diagnosis be-
tween viral and bacterial infection at the moment of 
admission, combined with the higher risk of associa-
tion with bacterial pneumonia in patients infected by 
influenza, resulted in a high frequency (84%) of em-
pirical treatment with antimicrobial agents associated 
with antiviral treatment.23,24
Infection by influenza A and B is associated with 
important morbidity and mortality in the population 
of organ transplant recipients, especially bone marrow 
and lung recipients.16,25,26 In this study, admission in 
the Intensive Care Unit, the need for mechanical ven-
tilation, and the use of vasoactive drugs and mortal-
ity were similar to the general population infected by 
H1N1.9,14,15 Although the condition of the risk popula-
tion for clinical complications has favored the admis-
sion of a higher number of patients with a less compro-
mised health state, the present findings indicate that 
kidney transplant recipients did not have additional 
risk for unfavorable evolution of influenza A.
In conclusion, the population of kidney transplant 
recipients infected with influenza A H1N1 analyzed 
in this study presented a high rate of acute allograft 
dysfunction, but no differences in other clinical, labo-
ratory and evolutionary findings when compared to 
the general population.
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